1-2 of 2
Opeyemi Jegede
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C

Mark H. O’Hara, Opeyemi Jegede, Mark A. Dickson, Angela M. DeMichele, Richard Piekarz, Robert J. Gray, Victoria Wang, Lisa M. McShane, Lawrence V. Rubinstein, David R. Patton, P. Mickey Williams, Stanley R. Hamilton, Adedayo Onitilo, James V. Tricoli, Barbara A. Conley, Carlos L. Arteaga, Lyndsay N. Harris, Peter J. O’Dwyer, Alice P. Chen, Keith T. Flaherty
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (1): 56–64.
https://doi.org/10.1158/1078-0432.CCR-24-0036
Published: 06 January 2025
View article titled, Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C
Open the PDF for Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C in another window
Includes: Supplementary data
Journal Articles

irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial

Jean-Christophe Pignon, Opeyemi Jegede, Sachet A. Shukla, David A. Braun, Christine E. Horak, Megan Wind-Rotolo, Yuko Ishii, Paul J. Catalano, Jonian Grosha, Abdallah Flaifel, Jesse S. Novak, Kathleen M. Mahoney, Gordon J. Freeman, Arlene H. Sharpe, F. Stephen Hodi, Robert J. Motzer, Toni K. Choueiri, Catherine J. Wu, Michael B. Atkins, David F. McDermott, Sabina Signoretti
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (7): 2174–2184.
https://doi.org/10.1158/1078-0432.CCR-18-3206
Published: 01 April 2019
View article titled, irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial
Open the PDF for irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial in another window
Includes: Supplementary data